SLS SELLAS Life Sciences Group Inc

Price (delayed)

$1.33

Market cap

$74.84M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.34

Enterprise value

$73.11M

SELLAS is a late-stage clinical biopharmaceutical company focused on the development of novel cancer immunotherapeutics for a broad range of cancer indications. SELLAS' lead product candidate, GPS, is licensed from ...

Highlights

SLS's EPS is up by 37% year-on-year and by 13% since the previous quarter

SELLAS Life Sciences Group's net income has increased by 10% YoY and by 2.6% QoQ

SELLAS Life Sciences Group's debt has increased by 41% QoQ but it has decreased by 4.1% YoY

SELLAS Life Sciences Group's equity has plunged by 108% from the previous quarter

The gross profit has plunged by 100% YoY

Sector: Healthcare

Industry: Biotechnology

Website: http://www.sellaslifesciences.com

Peers: OMER OMGA

Key stats

What are the main financial stats of SLS

Market

Shares outstanding

56.27M

Market cap

$74.84M

Enterprise value

$73.11M

Valuations

Price to earnings (P/E)

N/A

Price to book (P/B)

N/A

Price to sales (P/S)

N/A

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

N/A

Earnings

Revenue

EBIT

-$37.34M

EBITDA

-$36.85M

Free cash flow

-$31.41M

Per share

EPS

-$1.34

Free cash flow per share

-$1.13

Book value per share

-$0.25

Revenue per share

TBVPS

$0.15

Balance sheet

Total assets

$6.22M

Total liabilities

$14.2M

Debt

$906,000

Equity

-$7.98M

Working capital

-$10.56M

Liquidity

Debt to equity

-0.11

Current ratio

0.23

Quick ratio

0.19

Net debt/EBITDA

0.05

Margins

EBITDA margin

N/A

Gross margin

N/A

Net margin

N/A

Operating margin

N/A

Efficiency

Return on assets

-241%

Return on equity

-2,405.5%

Return on invested capital

N/A

Return on capital employed

N/A

Return on sales

N/A

Dividend

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

SLS stock price

How has the SELLAS Life Sciences Group stock price performed over time

Intraday

-1.48%

1 week

-8.9%

1 month

1.53%

1 year

-11.92%

YTD

25.47%

QTD

31.68%

Financial performance

How have SELLAS Life Sciences Group's revenue and profit performed over time

Revenue

Gross profit

Operating income

-$37.87M

Net income

-$37.34M

Gross margin

N/A

Net margin

N/A

The gross profit has plunged by 100% YoY

The revenue has dropped by 100% year-on-year

The operating income has grown by 10% YoY and by 3.2% from the previous quarter

SELLAS Life Sciences Group's net income has increased by 10% YoY and by 2.6% QoQ

Growth

What is SELLAS Life Sciences Group's growth rate over time

Valuation

What is SELLAS Life Sciences Group stock price valuation

P/E

N/A

P/B

N/A

P/S

N/A

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

N/A

SLS's EPS is up by 37% year-on-year and by 13% since the previous quarter

SELLAS Life Sciences Group's equity has plunged by 108% from the previous quarter

The revenue has dropped by 100% year-on-year

Efficiency

How efficient is SELLAS Life Sciences Group business performance

The company's return on equity has shrunk by 199% QoQ

SELLAS Life Sciences Group's return on assets has decreased by 47% YoY and by 21% QoQ

Dividends

What is SLS's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for SLS.

Financial health

How did SELLAS Life Sciences Group financials performed over time

The total assets is 56% smaller than the total liabilities

The quick ratio has plunged by 83% YoY and by 46% from the previous quarter

SLS's current ratio has dropped by 80% year-on-year and by 48% since the previous quarter

SELLAS Life Sciences Group's debt is 111% higher than its equity

The debt to equity has plunged by 158% YoY but it has grown by 35% from the previous quarter

SELLAS Life Sciences Group's equity has plunged by 108% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.